Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD

References

• Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121(5 Suppl): 121-6S.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2006;343:269-80.
   Google Scholar
• Foster TS, Miller JD, Marton JP, Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. COPD 2006;3:211-18.
   PubMedGoogle Scholar
• Menzin J, Boulanger L, Marton J, The economic burden of chronic obstructive pulmonary disease (COPD) in a US Medicare population. Respir Med 2008;102:1248-56.
   PubMed Web of Science ®Google Scholar
• American Lung Association. Research on chronic obstructive pulmonary disease. Available at: http://lungaction.org/lungusa/alert-description.html?alert_id=2956848 . Accessed: 27 January 2009.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Executive Summary. National Institutes of Health: National Heart, Lung, and Blood Institute. Updated 2008. Available at: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=2003. Accessed 27 January 2009.
   Google Scholar
• MacIntyre N, Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:530-5.
   PubMedGoogle Scholar
• Grasso ME, Weller WE, Shaffer TJ, Capitation, managed care, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:133-8.
   PubMed Web of Science ®Google Scholar
• Hilleman DE, Dewan N, Malesker M, Pharmacoeconomic evaluation of COPD. Chest 2000;118:1278-85.
   PubMed Web of Science ®Google Scholar
• Mapel DW, Hurley JS, Frost FJ, Health care utilization in chronic obstructive pulmonary disease. A case-control study in a Health Maintenance Organization. Arch Intern Med 2000;160:2653-8.
   PubMed Web of Science ®Google Scholar
• Strassels SA, Smith DH, Sullivan SD, The costs of treating COPD in the United States. Chest 2001;119:344-52.
   PubMed Web of Science ®Google Scholar
• Halpern MT, Stanford RH, Borker R. The burden of COPD in the USA: results from the Confronting COPD survey. Respir Med 2003;97(Suppl C):S81-9.
   PubMedGoogle Scholar
• Tsai C-L, Sobrino JA, Camargo CA. National study of emergency department visits for acute exacerbation of chronic obstructive pulmonary disease, 1993-2005. Acad Emerg Med 2008;15:1275-83.
   PubMed Web of Science ®Google Scholar
• Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD 2005;2:35-41.
   PubMedGoogle Scholar
• Decramer M, Nici L, Nardini S, Targeting the COPD exacerbation. Respir Med 2008;102(Suppl 1):S3-15.
   PubMedGoogle Scholar
• Szafranski W, Cukier A, Ramirez A, Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Pauwels R, Vestbo J, Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
   PubMed Web of Science ®Google Scholar
• Ferguson GR, Anzueto A, Fei R, Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med 2008;102:1099-108.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
   PubMed Web of Science ®Google Scholar
• Lee TA, Wilke C, Joo M, Outcomes associated with tiotropoium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009;169:1403-10.
   PubMed Web of Science ®Google Scholar
• Soriano JB, Kiri VA, Pride NB, Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003;2:67-74.
   PubMedGoogle Scholar
• Rascati KL, Stanford RH, Borker R. A comparison of the risk of hospitalizations due to chronic obstructive pulmonary disease in Medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. Clin Ther 2005;27:346-54.
   PubMed Web of Science ®Google Scholar
• Rascati KL, Akazawa M, Johnsrud M, Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Clin Ther 2007;29:1203-13.
   PubMed Web of Science ®Google Scholar
• Akazawa M, Hayflinger DC, Stanford RH, Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care 2008;14:438-48.
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Akazawa M, Dalal A, Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 μg/salmeterol 50 μg compared with ipratropium for chronic obstructive pulmonary disease in older adults. Am J Geriatr Pharmacother 2008;6:138-46.
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. 2007 NHLBI morbidity and mortality chartbook. Bethesda, Maryland: US Department of Health and Human Service, National Institutes of Health. 2007 . Available at: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm . Accessed 30 January 2009.
   Google Scholar
• US Department of Labor. Bureau of Labor Statistics. Consumer Price Indexes. Available at: http://www.bls.gov\CPI . Accessed 21 September 2009.
   Google Scholar
• Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009;64:728-35.
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Gutierrez B, Ory C, Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm 2008;14:176-85.
   PubMed Web of Science ®Google Scholar
• Make B, Hanania NA, ZuWallack R, The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2005;27:531-42
   PubMed Web of Science ®Google Scholar